Session Information
Date: Monday, September 23, 2019
Session Title: Neuropharmacology
Session Time: 1:45pm-3:15pm
Location: Les Muses Terrace, Level 3
Objective: The present study was undertaken in order find out the possible neuroprotective and antidepressant potential of Silymarin. The neuroprotective and antidepressant potential was evaluated in term of alleviating rotenone induced behavior deficits and biochemical alteration in experimental mice.
Background: Silymarin, an antioxidant derived from Silybum marianum, offers protection against chemical induced inflammation, hepatotoxicity, and cancer. Silymarin is nontoxic even at higher doses and is used in naturopathy worldwide against many diseases. It is recently reported that silymarin crosses the blood–brain barrier and enters the central nervous system.
Method: Parkinson was induced by rotenone (1 mg/kg i.p.) in saline. Chronic administration of rotenone (1 mg/kg i.p.) for a period of three weeks significantly impaired behavior activity, oxidative defense. Animals were divided in different treatment groups. Silymarin was used at 50, 100 and 200 mg/kg p.o. for the period of 21 days. Various behavior and biochemical parameters were evaluated at the end of the study.
Results: Chronic oral treatment silymarin for 21 days showed significant improvement in behavior activity in the Open field test, forced swim test, and tail suspension test. Also, reduction in plasma cortisol level as compared to disease control (rotenone treated) groups of animals. Results showed that the silymarin showed antidepressant activity in a dose dependent manner.
Conclusion: The outome of present study provides a scientific rationale for using of silymarin for the therapeutic management of depressive like symptoms associated with Parkinson’s disease.
References: Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP. Melatonin or silymarin reduces maneb‐and paraquat‐induced Parkinson’s disease phenotype in the mouse. Journal of Pineal Research. 2011 Mar;50(2):97-109.
To cite this abstract in AMA style:
D. Khatri. Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/alleviation-of-parkinsons-and-associated-depression-using-silymarin-in-rotenone-induced-mice-model-of-parkinsons-disease/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/alleviation-of-parkinsons-and-associated-depression-using-silymarin-in-rotenone-induced-mice-model-of-parkinsons-disease/